Abiomed logo
Abiomed ABMD

Quarterly report 2022-Q3
added 11-03-2022

report update icon

Abiomed Financial Ratios 2011-2026 | ABMD

Annual Financial Ratios Abiomed

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

0.1 42.6 48.1 118.5 108.1 107.5 22.6 126.8 48.1 624.5 -55.0

P/S

0.0 10.3 16.2 22.4 12.7 12.4 11.2 5.1 4.6 7.4 6.4

EPS

5 4.5 5.8 2.5 1.2 0.9 2.8 0.2 0.4 0.0 -0.3

EV (Enterprise Value)

-51.8 M 8.6 B 12.5 B 13.3 B 5.69 B 4.11 B 2.59 B 948 M 746 M 955 M 667 M

EBITDA per Share

5.62 K 5.97 5.32 3.81 2.23 1.62 0.774 0.276 0.426 0.0781 -0.263

EV/EBITDA

-0.2 31.3 51.6 78.8 58.1 59.2 81.0 83.8 42.8 309.4 -65.4

PEG

0.0 -1.92 0.38 1.08 3.14 -1.58 0.02 -2.54 0.05 5.57 -1.35

P/B

0.0 8.1 13.3 19.3 12.5 11.1 8.8 5.5 5.3 7.4 6.2

P/CF

0.1 31.9 59.8 97.2 87.1 67.0 67.4 45.0 30.7 494.3 -2808.5

ROE %

16.96 19.05 27.65 16.27 11.53 10.34 38.99 4.37 10.95 1.18 -11.22

ROA %

15.09 16.69 24.57 14.26 9.47 9.00 33.60 3.58 8.83 0.97 -8.93

ROCE %

17.26 22.98 23.71 22.39 18.75 17.25 9.59 4.78 11.57 1.16 -10.24

Current Ratio

9.1 4.8 6.4 5.8 4.7 6.2 5.6 3.9 4.3 4.9 3.8

DSO

39.2 36.7 43.1 43.0 44.3 47.4 50.4 48.4 53.0 59.1 55.5

DIO

192.9 217.3 228.0 185.9 180.5 193.6 153.3 136.4 172.5 165.9 124.6

DPO

76.2 79.1 90.7 87.3 106.6 67.9 94.9 75.8 88.9 102.9 104.3

Operating Cycle

232.1 254.1 271.1 228.9 224.8 241.0 203.7 184.8 225.4 225.0 180.1

Cash Conversion Cycle

155.9 175.0 180.4 141.7 118.3 173.1 108.8 109.1 136.5 122.1 75.8

All numbers in USD currency

Quarterly Financial Ratios Abiomed

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- 2.34 3.53 - 1.01 1.25 0.67 1.26 1.37 1.37 1.38 0.99 1.53 1.53 0.29 1.97 1 1 1.11 0.83 0.3 0.56 0.85 0.85 0.36 0.36 0.21 0.3 0.25 0.25 0.18 0.21 0.31 0.31 0.09 -0.04 0.11 0.11 0.03 -0.04 0.07 0.07 0.14 0.08 0.08 0.08 0.02 -0.12

EBITDA per Share

- 1.42 3.02 - 1.42 1.48 0.55 - 1.58 1.96 1.61 0.88 1.56 1.88 1.53 1.44 1.38 1.6 1.19 - 1.01 0.72 0.81 - 0.58 1.52 0.9 - 0.41 1.13 0.68 - 0.33 0.45 0.13 - 0.12 0.17 0.04 - 0.07 0.37 0.28 - 0.07 0.04 -0.04 -

ROE %

20.55 23.74 20.96 9.63 7.60 9.32 10.11 13.04 19.12 20.82 22.53 18.59 23.41 22.07 20.72 25.73 22.20 19.06 17.84 18.11 21.04 22.61 22.43 18.19 13.42 12.78 12.10 12.25 11.79 15.22 19.26 19.00 14.95 11.20 6.89 5.39 5.15 4.38 3.37 6.81 10.54 11.05 11.76 8.11 1.26 2.62 0.54 -4.39

ROA %

9.13 12.00 9.47 8.68 6.91 8.36 9.30 12.19 17.63 19.09 20.58 16.77 21.54 20.44 19.34 24.35 20.60 17.78 16.25 15.81 17.92 19.13 18.85 15.19 11.44 11.06 10.63 10.76 10.34 12.91 15.97 15.63 12.18 9.19 5.73 4.49 4.31 3.66 2.85 5.76 8.80 9.25 9.85 6.78 1.26 2.22 0.46 -3.49

ROCE %

16.35 20.85 21.45 9.72 15.38 16.53 17.82 16.50 19.59 20.65 21.70 22.58 25.55 26.16 26.77 27.05 28.07 27.82 25.75 18.16 24.24 23.25 33.35 30.90 35.95 34.91 33.25 27.77 34.75 36.68 32.29 18.72 21.58 17.47 11.29 6.04 8.18 7.46 13.18 18.24 20.14 19.89 9.79 -2.67 1.90 -1.28 -3.29 -

Current Ratio

- 10.8 - 9.8 10.0 10.5 9.7 9.1 8.6 9.1 8.5 8.1 8.0 8.5 9.2 9.0 9.1 9.4 9.2 8.1 8.3 7.7 7.7 5.6 6.0 6.2 8.3 7.7 8.5 8.8 8.0 7.2 5.3 5.4 5.8 5.5 5.9 6.0 5.8 5.2 5.7 6.6 6.3 5.6 6.2 6.5 6.6 4.9

DSO

- 16.2 7.6 - 31.2 32.8 16.9 36.0 34.2 32.1 36.3 51.4 40.2 37.2 39.4 39.3 37.0 32.2 34.5 35.3 36.2 38.1 37.1 38.1 38.5 35.0 37.3 35.3 39.3 38.0 39.5 37.4 37.9 33.7 41.4 44.2 43.5 41.6 45.2 45.8 46.2 44.3 47.3 44.4 46.5 42.5 46.3 -

DIO

- 95.4 42.2 - 168.8 176.4 84.4 161.9 183.8 191.4 211.3 229.9 207.0 203.1 220.7 188.0 181.7 160.2 162.0 147.2 159.8 163.6 150.0 158.7 152.7 159.7 169.0 - - - - - - - - - - - - - - - - - - - - -

DPO

- 32.7 15.9 - 57.2 59.7 33.1 57.9 50.3 54.9 71.3 81.6 72.2 70.1 81.0 71.8 64.5 63.8 75.3 69.1 70.6 62.1 69.7 83.3 68.8 59.1 53.8 - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- 111.6 49.9 - 200.0 209.1 101.3 197.9 218.1 223.5 247.5 281.2 247.2 240.2 260.1 227.3 218.6 192.4 196.5 182.5 196.0 201.7 187.0 196.8 191.2 194.7 206.3 35.3 39.3 38.0 39.5 37.4 37.9 33.7 41.4 44.2 43.5 41.6 45.2 45.8 46.2 44.3 47.3 44.4 46.5 42.5 46.3 -

Cash Conversion Cycle

- 78.9 34.0 - 142.8 149.4 68.2 140.0 167.8 168.6 176.3 199.7 175.0 170.2 179.2 155.5 154.2 128.6 121.3 113.4 125.4 139.6 117.3 113.5 122.4 135.5 152.6 35.3 39.3 38.0 39.5 37.4 37.9 33.7 41.4 44.2 43.5 41.6 45.2 45.8 46.2 44.3 47.3 44.4 46.5 42.5 46.3 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Abiomed, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Alphatec Holdings Alphatec Holdings
ATEC
$ 11.75 -3.29 % $ 1.76 B usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Delcath Systems Delcath Systems
DCTH
$ 8.98 -1.32 % $ 322 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.41 0.38 % $ 121 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Inogen Inogen
INGN
$ 6.32 -2.02 % $ 168 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.35 - $ 21.8 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 100.97 1.78 % $ 1.28 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 62.4 -1.33 % $ 3.4 B britainBritain
LENSAR LENSAR
LNSR
$ 5.56 -8.4 % $ 64 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
AxoGen AxoGen
AXGN
$ 32.61 2.71 % $ 1.5 B usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.56 -0.19 % $ 1.13 B usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 86.58 -0.68 % $ 111 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Electromed Electromed
ELMD
$ 24.7 0.86 % $ 209 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
InspireMD InspireMD
NSPR
$ 1.79 3.47 % $ 115 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
$ 11.72 -1.26 % $ 464 M curacaoCuracao
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.7 3.3 % $ 38.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.16 -6.09 % $ 3.37 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.15 -4.63 % $ 180 M canadaCanada
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Penumbra Penumbra
PEN
$ 334.17 -0.41 % $ 13 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.48 10.7 % $ 1.55 B usaUSA
Myomo Myomo
MYO
$ 0.7 -1.83 % $ 29.3 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 225.5 -0.7 % $ 15.9 B usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 2.4 -1.64 % $ 141 M israelIsrael
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.91 4.83 % $ 146 M franceFrance
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.82 -3.05 % $ 163 M usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.91 -3.4 % $ 373 M usaUSA
Outset Medical Outset Medical
OM
$ 3.53 -2.35 % $ 53.7 K usaUSA